142 related articles for article (PubMed ID: 38536949)
21. A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer.
Chen C; Shen M; Liao H; Guo Q; Fu H; Yu J; Duan Y
J Nanobiotechnology; 2021 Feb; 19(1):55. PubMed ID: 33632232
[TBL] [Abstract][Full Text] [Related]
22. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
da Motta LL; Ledaki I; Purshouse K; Haider S; De Bastiani MA; Baban D; Morotti M; Steers G; Wigfield S; Bridges E; Li JL; Knapp S; Ebner D; Klamt F; Harris AL; McIntyre A
Oncogene; 2017 Jan; 36(1):122-132. PubMed ID: 27292261
[TBL] [Abstract][Full Text] [Related]
23. Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer.
Staquicini FI; Hajitou A; Driessen WH; Proneth B; Cardó-Vila M; Staquicini DI; Markosian C; Hoh M; Cortez M; Hooda-Nehra A; Jaloudi M; Silva IT; Buttura J; Nunes DN; Dias-Neto E; Eckhardt B; Ruiz-Ramírez J; Dogra P; Wang Z; Cristini V; Trepel M; Anderson R; Sidman RL; Gelovani JG; Cristofanilli M; Hortobagyi GN; Bhujwalla ZM; Burley SK; Arap W; Pasqualini R
Elife; 2021 Jun; 10():. PubMed ID: 34060472
[TBL] [Abstract][Full Text] [Related]
24. Biomimetic oxygen delivery nanoparticles for enhancing photodynamic therapy in triple-negative breast cancer.
Fang H; Gai Y; Wang S; Liu Q; Zhang X; Ye M; Tan J; Long Y; Wang K; Zhang Y; Lan X
J Nanobiotechnology; 2021 Mar; 19(1):81. PubMed ID: 33743740
[TBL] [Abstract][Full Text] [Related]
25. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
26. Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer.
Jiang C; Wang X; Teng B; Wang Z; Li F; Zhao Y; Guo Y; Zeng Q
ACS Appl Mater Interfaces; 2021 Aug; 13(30):35248-35265. PubMed ID: 34284582
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic targeting with DABIL-4 depletes myeloid suppressor cells in 4T1 triple-negative breast cancer model.
Parveen S; Siddharth S; Cheung LS; Kumar A; Shen J; Murphy JR; Sharma D; Bishai WR
Mol Oncol; 2021 May; 15(5):1330-1344. PubMed ID: 33682324
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Targeted ECO/miR-200c Nanoparticles for Modulating Tumor Microenvironment and Treating Triple Negative Breast Cancer as Non-invasively Monitored by MR Molecular Imaging.
Schilb AL; Ayat NR; Vaidya AM; Hertz LM; Hall RC; Scheidt JH; Sun D; Sun Z; Gopalakrishnan R; Lu ZR
Pharm Res; 2021 Aug; 38(8):1405-1418. PubMed ID: 34389916
[TBL] [Abstract][Full Text] [Related]
29. Combining Tumor Microenvironment Modulating Nanoparticles with Doxorubicin to Enhance Chemotherapeutic Efficacy and Boost Antitumor Immunity.
Amini MA; Abbasi AZ; Cai P; Lip H; Gordijo CR; Li J; Chen B; Zhang L; Rauth AM; Wu XY
J Natl Cancer Inst; 2019 Apr; 111(4):399-408. PubMed ID: 30239773
[TBL] [Abstract][Full Text] [Related]
30. Treating metastatic triple negative breast cancer with CD44/neuropilin dual molecular targets of multifunctional nanoparticles.
Liang DS; Zhang WJ; Wang AT; Su HT; Zhong HJ; Qi XR
Biomaterials; 2017 Aug; 137():23-36. PubMed ID: 28528300
[TBL] [Abstract][Full Text] [Related]
31. Nanoparticle-integrated dissolving microneedles for the co-delivery of R848/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer.
Huang S; Wen T; Wang J; Wei H; Xiao Z; Li B; Shuai X
Acta Biomater; 2024 Mar; 176():344-355. PubMed ID: 38244662
[TBL] [Abstract][Full Text] [Related]
32. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
33. Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy.
Blaya-Cánovas JL; Griñán-Lisón C; Blancas I; Marchal JA; Ramírez-Tortosa C; López-Tejada A; Benabdellah K; Cortijo-Gutiérrez M; Cano-Cortés MV; Graván P; Navarro-Marchal SA; Gómez-Morales J; Delgado-Almenta V; Calahorra J; Agudo-Lera M; Sagarzazu A; Rodríguez-González CJ; Gallart-Aragón T; Eich C; Sánchez-Martín RM; Granados-Principal S
Mol Cancer; 2024 May; 23(1):83. PubMed ID: 38730475
[TBL] [Abstract][Full Text] [Related]
34. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
35. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shu S; Lin CY; He HH; Witwicki RM; Tabassum DP; Roberts JM; Janiszewska M; Huh SJ; Liang Y; Ryan J; Doherty E; Mohammed H; Guo H; Stover DG; Ekram MB; Brown J; D'Santos C; Krop IE; Dillon D; McKeown M; Ott C; Qi J; Ni M; Rao PK; Duarte M; Wu SY; Chiang CM; Anders L; Young RA; Winer E; Letai A; Barry WT; Carroll JS; Long H; Brown M; Liu XS; Meyer CA; Bradner JE; Polyak K
Nature; 2016 Jan; 529(7586):413-417. PubMed ID: 26735014
[TBL] [Abstract][Full Text] [Related]
36. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
37. Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy.
Zhang X; Liang Q; Cao Y; Yang T; An M; Liu Z; Yang J; Liu Y
J Nanobiotechnology; 2024 Jun; 22(1):319. PubMed ID: 38849938
[TBL] [Abstract][Full Text] [Related]
38. Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.
Yin H; Xiong G; Guo S; Xu C; Xu R; Guo P; Shu D
Mol Ther; 2019 Jul; 27(7):1252-1261. PubMed ID: 31085078
[TBL] [Abstract][Full Text] [Related]
39. Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer.
De Vita A; Liverani C; Molinaro R; Martinez JO; Hartman KA; Spadazzi C; Miserocchi G; Taraballi F; Evangelopoulos M; Pieri F; Bongiovanni A; Mercatali L; Tasciotti E; Ibrahim T
Sci Rep; 2021 Mar; 11(1):5107. PubMed ID: 33658580
[TBL] [Abstract][Full Text] [Related]
40. Engineered Exosomes Carrying miR-588 for Treatment of Triple Negative Breast Cancer Through Remodeling the Immunosuppressive Microenvironment.
Zhang Z; Luo X; Xue X; Pang M; Wang X; Yu L; Qian J; Li X; Tian M; Lu A; Lu C; Liu Y
Int J Nanomedicine; 2024; 19():743-758. PubMed ID: 38283199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]